MX2016002234A - Derivados de diazacarbazol como ligandos de tau para tomografia por emision de positrones (pet). - Google Patents
Derivados de diazacarbazol como ligandos de tau para tomografia por emision de positrones (pet).Info
- Publication number
- MX2016002234A MX2016002234A MX2016002234A MX2016002234A MX2016002234A MX 2016002234 A MX2016002234 A MX 2016002234A MX 2016002234 A MX2016002234 A MX 2016002234A MX 2016002234 A MX2016002234 A MX 2016002234A MX 2016002234 A MX2016002234 A MX 2016002234A
- Authority
- MX
- Mexico
- Prior art keywords
- fluoro
- aggregates
- dipyrido
- pyridin
- tau
- Prior art date
Links
- BZHCVCNZIJZMRN-UHFFFAOYSA-N 9h-pyridazino[3,4-b]indole Chemical class N1=CC=C2C3=CC=CC=C3NC2=N1 BZHCVCNZIJZMRN-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- FDMOHTOITMTGNG-UHFFFAOYSA-N 11-(6-fluoropyridin-3-yl)-4,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene Chemical compound Fc1ccc(cn1)-c1ccc2c(n1)[nH]c1ccncc21 FDMOHTOITMTGNG-UHFFFAOYSA-N 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 1
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052722 tritium Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un compuesto de fórmula general (Ver Fórmula) la que R es hidrógeno o tritio; F es Flúor o 18flúor; o a una sal de adición de ácido farmacéuticamente aceptable. Los compuestos de fórmula I incluyen 2-(6-fluoro-piridin-3-il)-9H-dipirido [2,3-b;3',4'-d]pirrol,3H-2-( 6-fluoro-piridin3-il)-9H-dipirido[2,3-b;3',4'-d]pirrol y [18F]-2-(6-fluoro-piridin-3-il)-9H-dipirido[2,3-b;3',4'-d]pirrol. Los compuestos se pueden usar para la unión y la formación de imágenes de agregados de tau y los agregados de lámina beta relacionados incluyendo entre otros agregados de beta-amiloide o agregados de alfa-sinucleína.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13187764 | 2013-10-08 | ||
| PCT/EP2014/071283 WO2015052105A1 (en) | 2013-10-08 | 2014-10-06 | Diazacarbazole derivatives as tau-pet-ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016002234A true MX2016002234A (es) | 2016-06-06 |
| MX373153B MX373153B (es) | 2020-04-21 |
Family
ID=49301396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002234A MX373153B (es) | 2013-10-08 | 2014-10-06 | Derivados de diazacarbazol como ligandos de tau para tomografía por emisión de positrones (pet). |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10004817B2 (es) |
| EP (1) | EP3055308B1 (es) |
| JP (1) | JP6194416B2 (es) |
| KR (1) | KR101770531B1 (es) |
| CN (1) | CN105358558B (es) |
| AR (1) | AR097931A1 (es) |
| AU (1) | AU2014333996B2 (es) |
| CA (1) | CA2917191C (es) |
| CL (1) | CL2016000728A1 (es) |
| CR (1) | CR20150663A (es) |
| DK (1) | DK3055308T3 (es) |
| EA (1) | EA028483B1 (es) |
| ES (1) | ES2657121T3 (es) |
| HR (1) | HRP20180049T1 (es) |
| HU (1) | HUE035413T2 (es) |
| IL (1) | IL243249A0 (es) |
| LT (1) | LT3055308T (es) |
| MA (1) | MA38935B1 (es) |
| MX (1) | MX373153B (es) |
| MY (1) | MY190196A (es) |
| NO (1) | NO3055308T3 (es) |
| PE (1) | PE20160159A1 (es) |
| PH (1) | PH12016500249A1 (es) |
| PL (1) | PL3055308T3 (es) |
| PT (1) | PT3055308T (es) |
| RS (1) | RS56777B1 (es) |
| SG (1) | SG11201602786UA (es) |
| SI (1) | SI3055308T1 (es) |
| TW (1) | TWI513698B (es) |
| UA (1) | UA116164C2 (es) |
| WO (1) | WO2015052105A1 (es) |
| ZA (1) | ZA201509013B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2247558T (pt) | 2008-02-14 | 2022-03-21 | Lilly Co Eli | Novos agentes de imagiologia para deteção de disfunção neurológica |
| RS56777B1 (sr) | 2013-10-08 | 2018-04-30 | Hoffmann La Roche | Derivati diazakarbazola kao tau-pet-ligandi |
| KR102618139B1 (ko) | 2014-05-13 | 2023-12-27 | 에프. 호프만-라 로슈 아게 | 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도 |
| CN107207508B (zh) * | 2015-02-02 | 2020-02-28 | Ucb生物制药私人有限公司 | 9h-吡咯并-二吡啶衍生物 |
| EP3118202A1 (en) | 2015-07-15 | 2017-01-18 | AC Immune S.A. | Dihydropyridopyrrole derivatives as tau-pet-ligands |
| WO2017009454A1 (en) | 2015-07-15 | 2017-01-19 | Ac Immune S.A. | Novel imaging compounds |
| JP7197476B2 (ja) * | 2016-07-22 | 2022-12-27 | エーシー・イミューン・エス・アー | タウタンパク質凝集体を画像化するための化合物 |
| JP7059270B2 (ja) * | 2016-07-22 | 2022-04-25 | エーシー・イミューン・エス・アー | タウタンパク質凝集体を画像化するための化合物 |
| WO2018024642A1 (en) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
| WO2018024643A1 (en) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
| HRP20210145T1 (hr) * | 2016-09-09 | 2021-03-05 | F. Hoffmann - La Roche Ag | Postupak za dobivanje 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-b;3',4'-d]pirola |
| WO2019145292A1 (en) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| IL275995B2 (en) * | 2018-01-24 | 2023-09-01 | Ac Immune Sa | A new method for the preparation of imaging compound |
| KR102789462B1 (ko) * | 2018-01-24 | 2025-04-03 | 에이씨 이뮨 에스에이 | Pet 이미징을 위한 진단 조성물, 진단 조성물의 제조 방법 및 진단에서의 그 용도 |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2247558T (pt) * | 2008-02-14 | 2022-03-21 | Lilly Co Eli | Novos agentes de imagiologia para deteção de disfunção neurológica |
| US8932557B2 (en) * | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| KR101764556B1 (ko) | 2008-06-11 | 2017-08-02 | 제넨테크, 인크. | 디아자카르바졸 및 사용 방법 |
| WO2010011964A2 (en) | 2008-07-24 | 2010-01-28 | Siemens Medical Solutions Usa, Inc. | Imaging agents useful for identifying ad pathology |
| CA2756137C (en) | 2009-03-23 | 2015-11-24 | Siemens Medical Solutions Usa, Inc. | Imaging agents for detecting neurological disorders |
| US8691187B2 (en) * | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| US20110183938A1 (en) | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
| US20150368244A1 (en) * | 2011-01-31 | 2015-12-24 | Genentech, Inc. | Diazacarbazoles and methods of use |
| RS56777B1 (sr) * | 2013-10-08 | 2018-04-30 | Hoffmann La Roche | Derivati diazakarbazola kao tau-pet-ligandi |
-
2014
- 2014-10-06 RS RS20180058A patent/RS56777B1/sr unknown
- 2014-10-06 HR HRP20180049TT patent/HRP20180049T1/hr unknown
- 2014-10-06 CA CA2917191A patent/CA2917191C/en active Active
- 2014-10-06 CN CN201480037389.5A patent/CN105358558B/zh active Active
- 2014-10-06 JP JP2016515518A patent/JP6194416B2/ja active Active
- 2014-10-06 TW TW103134795A patent/TWI513698B/zh active
- 2014-10-06 MX MX2016002234A patent/MX373153B/es active IP Right Grant
- 2014-10-06 HU HUE14781169A patent/HUE035413T2/en unknown
- 2014-10-06 KR KR1020167008013A patent/KR101770531B1/ko active Active
- 2014-10-06 WO PCT/EP2014/071283 patent/WO2015052105A1/en not_active Ceased
- 2014-10-06 NO NO14781169A patent/NO3055308T3/no unknown
- 2014-10-06 PT PT147811699T patent/PT3055308T/pt unknown
- 2014-10-06 ES ES14781169.9T patent/ES2657121T3/es active Active
- 2014-10-06 AR ARP140103712A patent/AR097931A1/es active IP Right Grant
- 2014-10-06 EP EP14781169.9A patent/EP3055308B1/en active Active
- 2014-10-06 SG SG11201602786UA patent/SG11201602786UA/en unknown
- 2014-10-06 LT LTEP14781169.9T patent/LT3055308T/lt unknown
- 2014-10-06 UA UAA201604290A patent/UA116164C2/uk unknown
- 2014-10-06 SI SI201430549T patent/SI3055308T1/en unknown
- 2014-10-06 PL PL14781169T patent/PL3055308T3/pl unknown
- 2014-10-06 EA EA201690515A patent/EA028483B1/ru not_active IP Right Cessation
- 2014-10-06 AU AU2014333996A patent/AU2014333996B2/en active Active
- 2014-10-06 DK DK14781169.9T patent/DK3055308T3/en active
- 2014-10-06 MY MYPI2016000604A patent/MY190196A/en unknown
- 2014-10-06 PE PE2015002706A patent/PE20160159A1/es active IP Right Grant
-
2015
- 2015-12-10 ZA ZA2015/09013A patent/ZA201509013B/en unknown
- 2015-12-15 CR CR20150663A patent/CR20150663A/es unknown
- 2015-12-21 IL IL243249A patent/IL243249A0/en active IP Right Grant
-
2016
- 2016-02-04 PH PH12016500249A patent/PH12016500249A1/en unknown
- 2016-03-25 MA MA38935A patent/MA38935B1/fr unknown
- 2016-03-30 CL CL2016000728A patent/CL2016000728A1/es unknown
- 2016-04-07 US US15/093,366 patent/US10004817B2/en active Active
-
2018
- 2018-05-15 US US15/980,080 patent/US11058781B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016002234A (es) | Derivados de diazacarbazol como ligandos de tau para tomografia por emision de positrones (pet). | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| PH12015501452A1 (en) | Novel quinolone derivatives | |
| MY183398A (en) | Derivatives of azaindazole or diazaindazole type for treating pain | |
| MX2016003422A (es) | Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen. | |
| PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
| PH12014502605A1 (en) | Uracyl spirooxetane nucleosides | |
| NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| MX2012004420A (es) | Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes. | |
| EA201301182A1 (ru) | Получение гадобутрола высокой чистоты | |
| UA114906C2 (uk) | Гетероциклільні сполуки як інгібітори мек | |
| MY150778A (en) | Fused heterocyclic compound | |
| GEP201706783B (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| MX338887B (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble. | |
| NZ704799A (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| MX336505B (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| EP4582424A3 (en) | 1,2-naphthoquinone derivative and method for preparing same | |
| NZ711343A (en) | Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation | |
| TN2016000003A1 (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MX2010006787A (es) | Análogos halogenados de agentes anti-fibroticos. | |
| PH12012501863A1 (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| MX364400B (es) | Compuestos de tetraciclina. | |
| NZ700356A (en) | Pyrazole compounds as sglt1 inhibitors | |
| MY162945A (en) | Azole derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |